Publications by authors named "James Revkin"

Claim this Profile

Mentions over time

Mentions by platform

Video Views

915,108

Total Likes

20,159

Extended Reach

2,919,500

Social Features

103
T
The mortality burden of cachexia or weight loss in patients with colorectal or pancreatic cancer: A systematic literature review.
Richard F Dunne, Jeffrey Crawford, Karen E Smoyer, Thomas D McRae, Michelle I Rossulek, James H Revkin

J Cachexia Sarcopenia Muscle· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Mortality burden of pre-treatment weight loss in patients with non-small-cell lung cancer: A systematic literature review and meta-analysis.
Philip D Bonomi, Jeffrey Crawford, Richard F Dunne, Eric J Roeland, Karen E Smoyer, James H Revkin

J Cachexia Sarcopenia Muscle· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Association between growth differentiation factor-15 and adverse outcomes among patients with heart failure: A systematic literature review.
Ali Javaheri, Mualla Ozcan, Lauren Moubarak, Karen E Smoyer, Michelle I Rossulek, James H Revkin

Heliyon· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase 2 study of the efficacy and safety of ponsegromab in patients with cancer cachexia: PROACC-1 study design.
John D Groarke, Jeffrey Crawford, Susie M Collins, Shannon L Lubaczewski, Danna M Breen, James Revkin

J Cachexia Sarcopenia Muscle· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Phase Ib First-In-Patient Study Assessing the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Ponsegromab in Participants with Cancer and Cachexia.
Jeffrey Crawford, Roberto A Calle, Susie M Collins, Yan Weng, Shannon L Lubaczewski, James H Revkin

Clin Cancer Res· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
ReducinG stroke by screening for UndiAgnosed atRial fibrillation in elderly inDividuals (GUARD-AF): Rationale and design of the GUARD-AF randomized trial of screening for atrial fibrillation with a 14-day patch-based continuous ECG monitor.
Daniel E Singer, Steven J Atlas, Alan S Go, Renato D Lopes, Steven A Lubitz, James H Revkin

Am Heart J· July 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Ending Gender Inequality in Cardiovascular Clinical Trial Leadership: JACC Review Topic of the Week.
Harriette G C Van Spall, Anuradha Lala, Thomas F Deering, Barbara Casadei, Faiez Zannad, James H Revkin

J Am Coll Cardiol· June 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Defining the path ahead for NOAC use in the pediatric population: A Cardiac Safety Research Consortium Think Tank.
Jonathan H Seltzer, Ann Farrell, Neil Goldenberg, Christoph Hornik, Daniel Keene, James H Revkin

Am Heart J· June 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cardiovascular event reduction with PCSK9 inhibition among 1578 patients with familial hypercholesterolemia: Results from the SPIRE randomized trials of bococizumab.
Paul M Ridker, Lynda M Rose, John J P Kastelein, Raul D Santos, Caimiao Wei, James Revkin

J Clin Lipidol· October 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Lipid-Reduction Variability and Antidrug-Antibody Formation with Bococizumab.
Paul M Ridker, Jean-Claude Tardif, Pierre Amarenco, William Duggan, Robert J Glynn, James Revkin

N Engl J Med· April 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cardiovascular Efficacy and Safety of Bococizumab in High-Risk Patients.
Paul M Ridker, James Revkin, Pierre Amarenco, Robert Brunell, Madelyn Curto

N Engl J Med· April 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluating bococizumab, a monoclonal antibody to PCSK9, on lipid levels and clinical events in broad patient groups with and without prior cardiovascular events: Rationale and design of the Studies of PCSK9 Inhibition and the Reduction of vascular Events (SPIRE) Lipid Lowering and SPIRE Cardiovascular Outcomes Trials.
Paul M Ridker, Pierre Amarenco, Robert Brunell, Robert J Glynn, J Wouter Jukema, James Revkin

Am Heart J· August 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Erratum to "Traditional and new composite endpoints in heart failure clinical trials: facilitating comprehensive efficacy assessments and improving trial efficiency" [Eur J Heart Fail 2016;18:482-489].
Stefan D Anker, Stefan Schroeder, Dan Atar, Jeroen J Bax, Claudio Ceconi, James Revkin

Eur J Heart Fail· June 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Traditional and new composite endpoints in heart failure clinical trials: facilitating comprehensive efficacy assessments and improving trial efficiency.
Stefan D Anker, Stefan Schroeder, Dan Atar, Jeroen J Bax, Claudio Ceconi, James Revkin

Eur J Heart Fail· May 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Rate of change in carotid intima-media thickness and vascular events: meta-analyses can not solve all the issues. A point of view.
Michiel L Bots, Allen J Taylor, John J P Kastelein, Sanne A E Peters, Hester M den Ruijter, James H Revkin

J Hypertens· September 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Surrogate endpoints in randomized cardiovascular clinical trials.
Michael Domanski, Stuart Pocock, Corine Bernaud, Jeffrey Borer, Nancy Geller, James Revkin

Fundam Clin Pharmacol· August 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Torcetrapib and carotid intima-media thickness in mixed dyslipidaemia (RADIANCE 2 study): a randomised, double-blind trial.
Michiel L Bots, Frank L Visseren, Gregory W Evans, Ward A Riley, James H Revkin

Lancet· July 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of torcetrapib on carotid atherosclerosis in familial hypercholesterolemia.
John J P Kastelein, Sander I van Leuven, Leslie Burgess, Greg W Evans, Jan A Kuivenhoven, James H Revkin

N Engl J Med· April 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Designs of RADIANCE 1 and 2: carotid ultrasound studies comparing the effects of torcetrapib/atorvastatin with atorvastatin alone on atherosclerosis.
John J P Kastelein, Sander I van Leuven, Gregory W Evans, Ward A Riley, James H Revkin

Curr Med Res Opin· April 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Biomarkers in the prevention and treatment of atherosclerosis: need, validation, and future.
James H Revkin, Charles L Shear, Hubert G Pouleur, Steven W Ryder, David G Orloff

Pharmacol Rev· March 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of torcetrapib on the progression of coronary atherosclerosis.
Steven E Nissen, Jean-Claude Tardif, Stephen J Nicholls, James H Revkin, Charles L Shear

N Engl J Med· March 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of torcetrapib, a novel cholesteryl ester transfer protein inhibitor, in individuals with below-average high-density lipoprotein cholesterol levels.
Michael H Davidson, James M McKenney, Charles L Shear, James H Revkin

J Am Coll Cardiol· November 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of torcetrapib, a novel cholesteryl ester transfer protein inhibitor, in individuals with below-average high-density lipoprotein cholesterol levels on a background of atorvastatin.
James M McKenney, Michael H Davidson, Charles L Shear, James H Revkin

J Am Coll Cardiol· November 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis